We analyzed the common driver genes of NSCLC and found that the mRNA expression of BRAF, KRAS and MET was higher after UBE3A-del (P < 2.2e-16, Figure 4(c)), which suggested that UBE3A-del patients might be sensitive to targeted therapy, which was in accordance with previous research from Mazieres et al. They revealed that the ICI response rate of lung cancer driven by KRAS, BRAF and MET was higher than that of other driver genes [30]. This evidence concerns the gene KRAS and lung carcinoma.